Tag: Calcimimetic

Clinical trials indicate that up to 21% of patients treated with cinacalcet may experience diarrhea. This common side effect is a well-documented gastrointestinal issue associated with the medication, which is used to manage conditions like hyperparathyroidism and parathyroid carcinoma.

In 2004, cinacalcet was approved by the FDA as the first agent in its class, definitively answering the question, 'What category is cinacalcet?' and ushering in a new treatment option for hyperparathyroidism. This medication is classified as a calcimimetic agent and is used to manage specific conditions involving overactive parathyroid glands.

Cinacalcet (brand name Sensipar) is a calcimimetic agent that works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands to extracellular calcium. It is an important medication for controlling high parathyroid hormone (PTH) levels, and the generic version offers a potentially more affordable option for many patients.

A 2024 meta-analysis revealed that the global prevalence of secondary hyperparathyroidism (SHPT) due to chronic kidney disease (CKD) is approximately 49.5% [1.7.1, 1.7.2]. A key medication to manage this is cinacalcet, but what's another name for cinacalcet? The most common brand name is Sensipar [1.2.1].

Although parathyroidectomy is a curative treatment for many cases of hyperparathyroidism, achieving high success rates, a subset of patients may experience persistent or recurrent disease. In these specific cases, doctors may prescribe **cinacalcet after parathyroidectomy** to manage ongoing high calcium and parathyroid hormone levels.

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), with a global prevalence estimated at 49.5%. To manage this and related conditions, a key question for patients and providers is, **what is Cinacalcet?** It's a vital medication for controlling hormone levels.

According to a 2013 meta-analysis, Cinacalcet significantly reduces the need for parathyroidectomy in patients with chronic kidney disease on dialysis. A calcimimetic drug, Cinacalcet tablets are primarily used to manage specific conditions involving overactive parathyroid glands and high calcium levels in the blood. This medication works by increasing the sensitivity of the body's calcium-sensing receptors, which in turn lowers parathyroid hormone (PTH) and calcium levels.